Relmada Therapeutics Hires Raj S. Pruthi As Chief Medical Officer-Urology

Relmada Therapeutics has appointed Raj S. Pruthi as Chief Medical Officer-Urology to advance its NDV-01 program following positive Phase 2 data for the treatment of non-muscle invasive bladder cancer (NMIBC); Pruthi's extensive experience in urologic oncology and clinical trials is expected to be crucial as Relmada prepares to initiate Phase 3 studies of NDV-01 in the first half of 2026.

Analysis

Relmada Therapeutics, Inc. (RLMD) has made a strategic leadership enhancement by appointing Dr. Raj S. Pruthi as Chief Medical Officer-Urology, a role pivotal for the advancement of its lead drug candidate, NDV-01. This development follows the positive initial Phase 2 data reported in April for NDV-01 in treating non-muscle invasive bladder cancer (NMIBC). Dr. Pruthi's extensive background, with over 25 years in urologic oncology, clinical trials, and prior leadership positions at enGene Holdings Inc. and Johnson & Johnson Innovative Medicine, is expected to be instrumental as Relmada prepares for the initiation of Phase 3 registrational studies for NDV-01, slated for the first half of 2026. This appointment, viewed with strongly positive sentiment (0.7), underscores the company's commitment to progressing NDV-01 through late-stage clinical development, a critical step towards potential regulatory submission and commercialization.

Key Decisions for Investors

• Investors should consider this appointment as a positive signal enhancing the clinical execution capabilities for Relmada's key NDV-01 program.
• Monitor progress towards the planned initiation of the NDV-01 Phase 3 study in the first half of 2026, as this will be a significant milestone for the company.
• Evaluate the strengthened leadership team in the context of the long-term development timeline and inherent risks associated with late-stage biotech clinical trials, particularly for a company focused on a lead asset.